EFFECT OF RITUXIMAB ON THE BLOOD CHOLESTEROL TRANSPORT SYSTEM IN PATIENTSWITH RHEUMATOID ARTHRITIS

EFFECT OF RITUXIMAB ON THE BLOOD CHOLESTEROL TRANSPORT SYSTEM IN PATIENTSWITH RHEUMATOID ARTHRITIS

Objective: To study the time course of changes in the indices of the blood lipid spectrum in patients with rheumatoid arthritis (RA) treated with rituximab during a 24-week follow-up. Subjects and methods. The study enrolled 39 patients (36 females and 3 males) with a valid diagnosis of RA; their me...

Full description

Saved in:

Bibliographic Details
Main Authors:	Tatyana Valentinovna Popkova, D S Novikova, O G Lineva, A A Novikov, E N Aleksandrova, E L Nasonov
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2010-08-01
Series:	Научно-практическая ревматология
Subjects:	rheumatoid arthritis chronic inflammation blood lipid spectrum rituximab
Online Access:	https://rsp.mediar-press.net/rsp/article/view/1076
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

ROLE OF MULTIPLEX CYTOKINE ANALYSIS IN THE EVALUATION OF THE EFFICACY OF RITUXIMAB DURING TREATMENT FOR RHEUMATOID ARTHRITIS
by: A. A. Novikov, et al.
Published: (2011-06-01)

CHANGES IN HEART RATE, HEART RATE VARIABILITY AND QT INTERVAL IN WOMEN WITH RHEUMATOID ARTHRITIS DURING RITUXIMAB TREATMENT
by: D. S. Novikova, et al.
Published: (2014-06-01)

Dynamics of the level of calprotectin in patients with rheumatoid arthritis during rituximab biosimilar (Acellbia “Biocad”) therapy
by: A. S. Avdeeva, et al.
Published: (2021-09-01)

Combination therapy for rheumatoid arthritis with rituximab and leflunomide(preliminary results of the Russian ARBITR Registry)
by: Evgeniy L'vovich Nasonov, et al.
Published: (2011-02-01)

Impact of rituximab therapy on endothelial function and other markers of atherosclerosisin patients with active rheumatoid arthritis
by: Aleksandr Vital'evich Volkov, et al.
Published: (2010-12-01)

THE RESULTS OF A PHASE III COMPARATIVE CLINICAL TRIAL OF RITUXIMAB (ACELLBIA® AND MABTHERA®) IN RHEUMATOID ARTHRITIS (THE BIORA STUDY)
by: E. L. Nasonov, et al.
Published: (2016-12-01)

EFFECT OF RITUXIMAB ON CARDIAC ELECTROPHYSIOLOGICAL PARAMETERS IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: L. I. Feiskhanova
Published: (2018-11-01)

Role of interleukin-6 in the development of atherosclerosis in rheumatoid arthritis
by: Elena Vasilyevna Udachkina, et al.
Published: (2013-10-01)

The results of investigating the efficacy and safety of non-medical switching from the original rituximab to its biosimilar in rheumatoid arthritis patients (AMBIRA study)
by: M. A. Korolev, et al.
Published: (2021-01-01)

RANGE AT RHEUMATOID ARTHRITIS AGAINST THERAPY THE RITUKSIMABY
by: Vadim Ivanovich Mazurov, et al.
Published: (2022-05-01)

THE EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR (ACELLBIA®) IN RHEUMATOID ARTHRITIS AS THE FIRST BIOLOGICAL AGENT: RESULTS OF PHASE III (ALTERRA) CLINICAL TRIAL
by: E. L. Nasonov, et al.
Published: (2017-09-01)

IMMUNOLOGICAL EFFECTS OF A RITUXIMAB BIOSIMILAR (ACELBIA, BIOCAD) IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. S. Avdeeva, et al.
Published: (2018-11-01)

Evaluation of the clinical efficiency of tocilizumab versus rituximab therapy in patients with rheumatoid arthritis
by: Anastasia Sergeyevna Avdeyeva, et al.
Published: (2012-08-01)

Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis
by: A. S. Avdeeva, et al.
Published: (2019-07-01)

THE EFFICACY AND SAFETY OF RITUXIMAB IN RHEUMATOID ARTHRITIS: NEW EVIDENCE
by: D. A. Kusevich, et al.
Published: (2017-09-01)

Efficacy, Safety and Predictors of Response to Rituximab in Treatment of Iraqi Patients with Active Rheumatoid Arthritis
by: Sarah Tareq Abdulazeez, et al.
Published: (2019-06-01)

Quality of life in patients with rheumatoid arthritis during rituximab therapy
by: Tatiana Alekseyevna Raskina, et al.
Published: (2013-06-01)

Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland)
by: A. S. Avdeeva, et al.
Published: (2019-03-01)

RITUXIMAB THERAPY MONITORING IN PATIENTS WITH RHEUMATOID ARTHRITIS HROUGH PERIPHERAL BLOOD GENE EXPRESSION ANALYSIS
by: E. V. Chetina, et al.
Published: (2014-06-01)

Dynamics of lymphocyte subpopulations, CD4+CD25+CD127- T regulatory cells in patients with rheumatoid arthritis during therapy with the rituximab biosimilar Acellbia
by: A. S. Avdeeva, et al.
Published: (2020-05-01)

Clinical efficacy of the rituximab biosimilar Acellbia® 600 mg in patients with active rheumatoid arthritis in clinical practice
by: D. A. Kusevich, et al.
Published: (2019-01-01)

Relationship between laboratory biomarkers and ultrasonographic signs of inflammation in patients with rheumatoid arthritis treated with a rituximab biosimilar
by: A. S. Avdeeva, et al.
Published: (2022-06-01)

TIME COURSE OF CHANGES IN THE SYNOVIAL FLUID LEVELS OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ATHRITIS PATIENTS DURING RITUXIMAB TREATMENT
by: A V Bezgin, et al.
Published: (2011-08-01)

Comparison of rituximab vs. cyclophosphamide in rheumatoid arthritis-associated interstitial lung disease and its correlation with spirometry
by: Mohammed Abdullah Saleem, et al.
Published: (2024-12-01)

Comparison of the efficacy and safety of the original rituximab and its biosimilar in routine clinical practice
by: D. A. Kusevich, et al.
Published: (2022-06-01)

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY AS A COMPLICATION OF RITUXIMAB THERAPY FOR RHEUMATOID ARTHRITIS (A CASE REPORT)
by: I. B. Bashkova, et al.
Published: (2018-09-01)

Role of blood cholesterol transport system disturbances in atherosclerosis development in rheumatoid arthritis
by: T. V. Popkova, et al.
Published: (2007-10-01)

Changes in serum lipids in patients with rheumatoid arthritis treated with a combination of tocilizumab and methotrexate compared with methotrexate alone for 24 weeks of observation
by: E. V. Udachkina, et al.
Published: (2015-11-01)

Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets
by: R. O. Dreval
Published: (2018-06-01)

THE ROLE OF LABORATORY BIOMARKERS IN PREDICTING THE EFFICIENCY OF RITUXIMAB THERAPY FOR RHEUMATOID ARTHRITIS: NEW EVIDENCE
by: A. S. Avdeeva, et al.
Published: (2017-07-01)

CHANGES OF BONE MINERAL DENSITY DURING FOUR-YEAR RITUXIMAB AND METHOTREXATE THERAPY IN POSTMENOPAUSAL WOMEN WITH RHEUMATOID ARTHRITIS
by: T. A. Raskina, et al.
Published: (2016-12-01)

Unusual presentation of rheumatoid arthritis in a 106‐year‐old woman: A rare case report
by: Ali ALQazzaz, et al.
Published: (2023-03-01)

Time course of bone mineral density changes during 4-year rituximab therapy in postmenopausal women with rheumatoid arthritis
by: T. A. Raskina, et al.
Published: (2015-09-01)

PROATHEROGENIC LIPID AND LIPOPROTEIN METABOLIC DISTURBANCES IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: E. V. Gerasimova, et al.
Published: (2017-07-01)

THE CLINICAL AND IMMUNOLOGICAL EFFECTS OF ANTI-B-CELL THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: Elena Nikolayevna Aleksandrova, et al.
Published: (2012-02-01)

Expert Panel consensus statements on the optimal usage of rituximab for the management of rheumatoid arthritis in India
by: Keerthi Talari, et al.
Published: (2021-01-01)

Ihmor necrosis factor-a inhibitors and cardiovascular risk in rheumatoid arthritis
by: Tatiana Valentinovna Popkova, et al.
Published: (2012-12-01)

EVALUATION OF THE FUNCTIONAL STATUS OF THE RUSSIAN POPULATION OF PATIENTSWITH RHEUMATOID ARTHRITIS ACCORDING THE DATA OF THE RAiSeR STUDY
by: O M Folomeyeva, et al.
Published: (2010-06-01)

The T-cell response to SARS-CoV- 2 vaccination persists beyond six months in rheumatoid arthritis patients treated with rituximab
by: Juliette Marin, et al.
Published: (2025-04-01)

USE OF MULTIPARAMETER ANALYSIS OF LABORATORY BIOMARKERS TO ASSESS RHEUMATOID ARTHRITIS ACTIVITY
by: A. A. Novikov, et al.
Published: (2016-02-01)